Notably, CNIH4 overexpression is linked to adverse outcomes in low-grade glioma (LGG) and cervical cancer, and its expression in cervical cancer is associated with tumor progression and the inhibition of ferroptosis (Xiao et al., 2023; Wang et al., 2023; Yang et al., 2023). Here, CNIH4 is linked to cervical cancer.